ScholarIQanswers from OpenAlex
Hospital do Desterro
InstitutionResearch output, impact & collaborations
Hospital do Desterro is a institution indexed in ScholarIQ from OpenAlex.
What is known about Hospital do Desterro?
ScholarIQrecord summary
Hospital do Desterro is a research organisation in Lisbon, PT. OpenAlex records 1,267 works and 39,866 citations for it. 349 researchers list it as their most recent affiliation.
How many works does Hospital do Desterro have?
ScholarIQindexed works
Hospital do Desterro has 1,267 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hospital do Desterro have?
ScholarIQcitation count
Hospital do Desterro has 39,866 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Hospital do Desterro?
ScholarIQresearcher count
Hospital do Desterro has 349 researchers in the ScholarIQ index.
What is the average h-index at Hospital do Desterro?
ScholarIQavg h-index
Hospital do Desterro has an average h-index of 19 in OpenAlex.
What is the ROR of Hospital do Desterro?
ScholarIQror
The ROR for Hospital do Desterro is on the source record.
What is the OpenAlex record for Hospital do Desterro?
ScholarIQopenalex
The OpenAlex for Hospital do Desterro is on the source record.
Who are the most-cited researchers behind Hospital do Desterro?
ScholarIQtop researchers by citations
What are the most-cited papers on Hospital do Desterro?
ScholarIQmost cited works
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi, Z. Reguiaï, Alice B. Gottlieb, Falk G. Bechara, C. Paul, Evangelos J. Giamarellos Bourboulis, A. Villani, Andreas Schwinn, Franziska Ruëff, Larisha Pillay Ramaya, Adam Reich, Inês Lobo, Rodney Sinclair, Thierry Passeron, Antonio Martorell, Pedro Mendes‐Bastos, Georgios Kokolakis, Pierre‐André Bécherel, Magdalena B. Wozniak, Angela Llobet Martinez, Xiaoling Wei, Lorenz Uhlmann, Anna Passera, Deborah Keefe, Ruvie Martin, Clarice Field, Li Chen, Marc Vandemeulebroecke, Shoba Ravichandran, Elisa Muscianisi
Update on Atopic Dermatitis
Tiago Torres, Eduarda Osório Ferreira, Margarida Gonçalo, Pedro Mendes‐Bastos, Manuela Selores, Paulo Filipe
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres, L. Puig, Ronald Vender, Charles Lynde, Stefano Piaserico, J.M. Carrascosa, Paolo Gisondi, E. Daudén, Curdin Conrad, Pedro Mendes‐Bastos, Paulo Ferreira, Luíz Leite, Justin D. Lu, Joana Valério, Manfredo Bruni, Francesco Messina, Alessia Nidegger, Mar Llamas‐Velasco, E. del Alcázar, Asfandyar Mufti, Kyra White, Giacomo Caldarola, Laetitia Teixeira, Paolo Romanelli, K. Desai, Spyridon Gkalpakiotis, Marco Romanelli, Jensen Yeung, Miguel Nogueira, Andrea Chiricozzi
Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions
Pedro Mendes‐Bastos, Ana Brasileiro, Pavel Kolkhir, Stefan Frischbutter, Jörg Scheffel, Sherezade Moñino‐Romero, Marcus Maurer
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
Tiago Torres, L. Puig, Ronald Vender, Jensen Yeung, J.M. Carrascosa, Stefano Piaserico, Paolo Gisondi, Charles Lynde, Paulo Ferreira, Pedro Mendes‐Bastos, E. Daudén, Luíz Leite, Joana Valério, E. del Alcázar-Viladomiu, E. Vilarrasa Rull, Mar Llamas‐Velasco, Federico Pirrò, Francesco Messina, Manfredo Bruni, Gaetano Licata, Federica Ricceri, Alessia Nidegger, Jan Hugo, Asfandyar Mufti, A. Daponte, Laetitia Teixeira, Anna Balato, Marco Romanelli, Francesca Prignano, Spyridon Gkalpakiotis, Curdin Conrad, Elizabeth Lazaridou, Natalia Rompoti, Marina Papoutsaki, Miguel Nogueira, Andrea Chiricozzi
How much of the research on Hospital do Desterro is open access?
ScholarIQopen access share
83%OPEN ACCESS